ClinicalTrials.gg
RecruitingNCT07139873Updated Jun 3, 2026

A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)

A Phase 3 interventional study of DZD8586 and Bendamustine in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, sponsored by Dizal Pharmaceuticals. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by Dizal Pharmaceuticals · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 108 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in China — 39 open to participants now, 60 under way, 19 of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · China.

Planned enrollment
20th of 105
250 · median 89
Started
2025
with 11 others
Phase 3
25 of 108
9 open now
Primary completion
2029-01
later than 40 of 59 live
Registered
97th of 108
by date
Lead sponsor
3 of 108
Dizal Pharmaceuticals

Among the 108 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in China, this one is the 20th largest by planned enrollment of the 105 interventional ones that give a count, is one of 12 that started in 2025, is one of 25 in phase 3, reaches primary completion later than 40 of the 59 other live ones, and was the 97th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

39 of the 108 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in China are open now. Recruiting first, the newest first:

33 more — sign in →

All 39 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 188 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 108 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in China, or all of them as a file.
02

Study summary

This is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD8586 versus investigator's choice in participants with chronic lymphocytic leukemia/small lymphocytic lymphoma who have progressed following prior therapy.

Primary objective of this study is to assess the efficacy using progression free survival assessed by independent review committee as primary endpoint. Approximately 250 participants are estimated to be randomized into the study.

03

Conditions studied

  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female participants ≥ 18 years of age.
  2. performance status 0-2.
  3. Confirmed diagnosis of CLL/SLL with indication for treatment.
  4. Adequate bone marrow reserve and organ system functions.
  5. Participants willing to comply with restrictions.

Exclusion criteria

Exclusion Criteria:

  1. Any unresolved > Grade 1 adverse event at the time of starting study treatment.
  2. Known or suspected Richter transformation.
  3. Known or suspected CNS involvement.
  4. Previous or current therapy and comedications meet exclusion criteria.
  5. Participants with major cardiovascular disease, active infection, or uncontrolled systemic disease.
  6. Nausea and vomiting not controlled or chronic gastrointestinal diseases, unable to swallow the formulated product or previous bowel resection that would preclude adequate absorption.
  7. Women who are breast feeding.
  8. History of to active or inactive of DZD8586 or drugs with a similar chemical structure or class.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    Daily dose of DZD8586 (Birelentinib)

    Drug: DZD8586

  • Active comparator
    Investigator's choice

    Drug: Bendamustine · Drug: Idelalisib · Drug: Rituximab

Interventions

  • Orally, 50 mg, once daily until treatment discontinuation criterion is met.

    Also known as: Birelentinib

  • Administered intravenously

  • Administered orally

  • Administered intravenously

06

What researchers measure

Primary outcomes

  1. Progression free survival (PFS) assessed by Independent Review Committee (IRC)

    Time frame: Approximately 36 Months

Secondary outcomes

  1. PFS assessed by investigator

    Time frame: Approximately 36 Months

  2. Objective response rate (ORR) by IRC and investigator

    Time frame: Approximately 36 Months

07

Study locations

2 of 2 sites recruiting
  • First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
    Nanjing, Jiangsu, China
    Recruiting
  • National Clinical Research Center for Blood Diseases, Blood Disease Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College
    Tianjin, Tianjin Municipality, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Jan 2029, 40 months after the start.

Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's planned 40 months is below that.

Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2025
First posted
Aug 24, 2025
StartActual
Sep 8, 2025
Primary completionEst.
Jan 2029
CompletionEst.
Dec 2029
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07139873
Responsible party
Sponsor
First posted
Aug 24, 2025
Start date
Sep 8, 2025
Primary completion
Jan 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Jun 3, 2026

Study contacts

Cong Wei
Contact
Cong.Wei@dizalpharma.com
0086-21-61097873
Study Director
study director · Dizal Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Birelentinib

Start the discussion